PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes

Gdańsk, Poland – 24 October 2024 (07:00 CET) – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a wide range of autoimmune diseases, has launched a placebo-controlled Phase 2 clinical trial with PTG-007 Treg cell therapy in presymptomatic type-1 diabetes (T1D) patients, after receiving approval from the European Medicines Agency. … Continued

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that China’s National Intellectual Property Administration, PRC (CNIPA) has issued a notification to grant a patent for the intrathecal administration of the company’s cellular therapies in … Continued

Join us for the PolTREG H1 2024 financial results webinar!

We are pleased to invite you to our upcoming webinar, which will present the financial results for H1 2024 and PolTREG’s development plans. Join us on Friday, September 13, 2024, at 2:00 PM CEST, where you will hear directly from our company’s management: The webinar will be conducted in Polish and partially in English. Register … Continued

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

Gdańsk, Poland – 9 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces data showing that treatment with its Treg cell therapy, PTG-007, resulted in clinical remission for up to 12 years in patients with type-1 diabetes (T1D). A subset … Continued

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes. 

We are now expecting to enroll the first patients – mostly children – in the trial with PTG-007 this autumn. At PolTREG, we believe that T1D one day will be a preventable disease.  The trial is an important  step in that direction. By detecting the disease in high-risk patients we can start treating the disease … Continued

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

PolTREG will produce its PTG-007 therapy with blood received from patients selected by the UCC, and deliver the finished product to UCC for a payment. Patients will then be injected with the preparation – derived from their own blood – at UCC. While PTG-007 is not yet on the market, it is available in Poland … Continued

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

“At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG Chief Executive Officer. Here … Continued

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

Green light for PolTREG to start producing next-generation T-reg cell therapies at its own pharmaceutical plant: the company just received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment. We can now manufacture engineered T-reg cells at our state-of-the-art facility, including TCR-Tregs, CAR-Tregs and antigen-specific Tregs. These products offer exciting … Continued

PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered

At PolTREG, we are very excited to announce we have received a patent in the US protecting an important part of our business: the manufacturing of T-regulatory cells (T-regs) to treat Type-1 Diabetes (T1D), and ways the therapy is administered.  “The decision by the US Patent and Trademark Office (USPTO) complements our large intellectual property … Continued